and suffer higher complication rates including bleeding, compared to younger cohorts such that older people have generally been less likely to undergo revascularisation. Historically, selected patients have been shown to receive benefit from revascularisation from coronary bypass surgery (CABG) or percutaneous coronary intervention (PCI), though this has often been underutilised [2, 3] . However, perhaps as a result of improving stent and other technologies, PCI is now increasingly being utilised such that currently approximately A case is presented to first illustrate some contemporary and likely future developments in coronary stenting in the elderly, followed by a discussion of such issues.
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An 86-year-old independent but frail woman living at home, presented with recurrent chest pain and pulmonary oedema. Her past history included recurrent medically managed non ST elevation myocardial infarction, heart failure and steroid responsive idiopathic thrombocytopenia ( Angiography revealed an ostial left main coronary artery (LMCA) 90% stenosis, mid left anterior descending (LAD) 70% stenosis and a first diagonal 80% stenosis (Figure 1 ). She was deemed to be unsuitable for coronary artery bypass grafting due to frailty and co morbidities. Haematology consulted suggested if coronary intervention were to be contemplated ideally bare metal stenting (BMS) should be considered to lessen the time on dual antiplatelet therapy, with increased prednisone dose and close monitoring of platelet count. She underwent coronary stenting to both LMCA and LAD stenosis. A 6F XB3.0 guide catheter was used with a 0.014 Run-through Floppy wire (Terumo Corp, Tokyo, Japan, via the femoral approach. A novel drug eluting stent (DES) (Synergy 3.5 × 12 mm, Boston Scientific, Natick, MA, USA) was used for the LMCA, and a BMS (2.75 × 12 mm integrity, Boston Scientific) to the LAD. The diagonal branch was not treated on this occasion given a small myocardial territory subtended. The Synergy stent has a novel design with a bioabsorbable polymer that elutes everolimus placed only on the abluminal stent surface, and is further discussed below. The patient remains well at 3 months post discharge, with a plan to continue aspirin, taper her prednisone, and stop her clopidogrel at 6 months or earlier, if there was any evidence of intolerance or bleeding secondary to the combination, with this duration determined by the Synergy drug eluting stent rather than the bare metal stent.
Coronary disease remains a leading cause of death in elderly patients, who have an increased risk of coronary events, mortality, cardiogenic shock, recurrent ischemia and re-hospitalization [1] . There is a general perception that the elderly have worse outcomes 12% of PCI is performed in patients aged ≥ 80 years [4, 5] . Many contemporary studies demonstrate similar or only slightly lower rates of successful reperfusion with PCI compared to younger age groups in the setting of PCI for acute myocardial infarction (TIMI 3 flow = 97.3% in > 80 year old v 98.3% in < 80 year old sp = 0.24) [6] . Moreover, meta-analyses confirm that PCI can offer good clinical outcomes for octogenarians, with a 30-day mortality of 5.4% and 1 year survival of 87% [7] . Some of the developments that have contributed to these improved outcomes, and some likely future developments, are now discussed.
Bare Metal vs. Drug Eluting Stents in the Elderly
The use of DES has been less in older populations [8] , likely due to the perceived bleeding risks associated with prolonged dual antiplatelet therapy. A number of recent studies suggest any such bleeding risks may be less than previously estimated.
The XIMA (Xience or Vision Stents for the Management of Angina in the Elderly) multicentre randomized control trial compared the use of DES to BMS in patients > 80 years with ACS (68%) or stable angina (32%) at one year [9] . Dual antiplatelet therapy at 1 year was 32.2% for patients in the BMS group and 94.0% in the DES group. Myocardial infarction (4.3% vs. 8.7%, p = 0.01) and target vessel revascularization (2.0% vs. 7.0%, p = 0.001) were less frequent in the DES group. There was no difference in major haemorrhage (2.3% vs. 1.7%, p = 0.61), death (8.5% vs. 7.2%, p = 0.50), or cerebrovascular accident (1.5% vs. 1.2%, p = 0.77).
Similarly, observational studies also support the use of DES in older patients, even in the very elderly > 85 years old [8, 10, 11] . The use of DES was associated with reduced mortality compared to bare metal stents (BMS): age > 85 years (28.4% vs. 38.3%, p < 0.001); age 75 to 84 years (16.8% vs. 24.8%, p < 0.001) (median follow-up 640.8 ± 423.5 days). DES was associated with lower re hospitalization for myocardial infarction: age > 85 years (9.2% vs. 11.6%, p < 0.001); age 75 to 84 years (7.4% vs. 9.4%, p < 0.001) (median follow-up 640.8 ± 423.5 days) [8] . The benefits of DES appear to persist even over long term follow up, with another study demonstrating reductions in myocardial infarction (8.6% vs. 16.6%, p = 0.038) and target vessel revascularization rates (7.9% vs. 21.9%; p = 0.003) at 5 years in patients aged > 75 years compared to BMS [12] . Furthermore, there was no significant increase in bleeding events in those with DES (13.8% vs. 12.2%, p = 0.882) [12] .
Access Route Choice in the Elderly
Following a number of studies suggesting improved outcomes for radial vs. femoral access in elective PCI (RIVAL), the MATRIX trial suggested superiority for radial PCI in reducing bleeding complications and mortality in the general ACS population compared to those randomised to femoral access [12, 13] .
This preference for radial access PCI has been examined also in the elderly, with acceptable failure rates of the radial approach of 7.5-9.8%, requiring crossover to alternate access [14] [15] [16] [17] . Left radial access is a valid alternative, with reduced subclavian tortuosity (6% versus 32%, p = 0.002) observed [18] . While some studies suggest a longer cannulation and/or procedural time [15, 17] , other trials suggest that there is no significant difference with experienced operators [17] .
There is indeed increasing evidence that transradial access may provide benefit in the elderly. A randomized trial demonstrated that in patients aged over seventy-five, there was reduced major complications (bleeding requiring surgery or transfusion or stroke, 0% vs. 3.2%, p < 0.001) compared to femoral access. Additionally, there were reduced rates of access site bleeding (2.7% vs. 9.6%, p = 0.004), hematoma (4.5% vs. 10.9%, p = 0.006), or any vascular complication (7.1% vs. 23.7%, p < 0.001) with the radial approach as opposed to femoral [15] . Additionally, radial access is associated with reduced ambulation time, shorter CCU stays (3.6 ± 1.5 vs. 5.0 ± 3.2 days, p = 0.001), and even reduced duration of hospitalization (13.3 ± 7.4 days vs. 19.2 ± 11.1 days, p = 0.001) compared to femoral access in AMI patients > 80 years old [17, 19] .
Novel Stent Technologies
While novel stent technologies have not been specifically targeted to the elderly, there has been a rapid evolution of stent technology, with the emergence of bio-absorbable scaffolds, bio-absorbable polymers and even novel polymer-free stents that deliver antiproliferative agents. Such stent technology may eventually be less dependent on prolonged dual antiplatelet therapy, which would be ideal for those at high risk for bleeding including the elderly.
Bio-absorbable scaffolds comprise a fully bioresorbable Poly-LLactic Acid (PLLA) mechanical scaffold incorporating drug delivery similar to a DES, reviewed in detail elsewhere [20] . This mechanical scaffold provides support for approximately one year, and is completely resorbed by 4 years in a pig model [21] . A randomised trial comparing everolimus eluting bio-absorbable scaffolds (Absorb) compared to the second generation Xience DES (everolimus) demonstrated that there was no difference in cardiac death (0.6% vs. 0.1%), target vessel revascularisation (3.0% vs. 2.5%) or myocardial infraction (6.0% vs. 4.6%) from target lesion failure in the Absorb scaffold compared to DES at one year [22] , though there was a small increase in stent thrombosis (1.4% vs. 0.7%, P = 0.21) associated with the Absorb scaffold, particularly sub acutely between 24 hours and 30 days (0.9% vs. 0.1%, p = 0.04). At present the potential for such scaffolds to offer shorter duration antiplatelet agent use, has therefore not been met, but is a field of active investigation. These bioresorbable stents have similarly not been trialled specifically for LMCA stenting, nor particularly in the elderly, though again is likely to be an area of future investigation.
Bio-absorbable polymers involve the short-term delivery to the vessel wall of anti-proliferative polymers, often abluminally coated on the stent surface. The EVOLVE II randomised trial compared the second generation DES Promus element plus (everolimus) to the novel Synergy stent. This is a bio absorbable abluminal polymer eluting everolimus, used in the case discussed above [23] . The attraction of such a design is locally-delivered anti proliferative drug from a bio absorbable polymer -to potentially lessen restenosis -with a luminal stent surface of thin strut cobalt chromium alloy -to potentially lessen stent thrombosis and lessen the duration of antiplatelet use. To date, non-inferiority has been likely demonstrated, with no difference in cardiac death (0.5% vs. 0.9%, p = 0.34), myocardial infarction (5.4% vs. 5.0%, p = 0.68), target vessel revascularisation (2.6% vs. 1.7%, p = 0.21) and definite/probable stent thrombosis (0.4% vs. 0.6%, p = 0.5) at one year, but the question as to whether this technology will translate to reduced antiplatelet use remains under investigation.
Conclusions
PCI is becoming increasingly utilised in older populations, with several new approaches impacting upon decision-making. Drug eluting stents and radial access appear to provide robust benefits in the elderly. Advances in stent technologies are being actively evaluated, which may ultimately reduce the need for prolonged dual antiplatelet agents in the elderly.
